Absci Corp at JPMorgan Healthcare Conference Transcript
Good afternoon. Thanks for joining us for another session of the 44th JPMorgan Healthcare Conference. I am Brian Cheng, one of the senior biotech analysts here at the firm. On stage, we have Absci. I will now pass the mic to their CEO Sean McClain for a short presentation followed by a live audience Q&A.
Sean, welcome. The stage is yours.
Thank you, Brian. As Brian said, I'm Sean McClain, the founder and CEO of Absci. We're a generative AI drug creation company, and we're entering this really exciting new era where we're actually seeing the molecules that we designed in our AI not only go into the clinic but actually start to see proof of concept. Within the next 24 months we will have two Phase II readouts in androgenetic alopecia, as well as endometriosis.
We're looking to industrialize AI for drug discovery. We want to be able to leverage AI to figure out what biology we should be going after, what molecules we should
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
